Danish economic growth slowed sharply in the second quarter of 2026, with gross domestic product rising just 0.3 percent after a 1.5 percent increase in the first quarter.
Danmarks Statistik published the national accounts for the second quarter on Thursday, August 20, 2026. Avisen Danmark reports that total GDP growth came in at 0.3 percent, down from 1.5 percent in the first three months of the year.
GDP is the most widely used measure of the size of a national economy. Rises and falls indicate whether the economy is expanding or contracting. The Danmarks Statistik release shows growth remained positive quarter on quarter, but clearly decelerated from the strong start to the year.
Pharmaceutical boost fades
According to the agency’s sector breakdown, the pharmaceutical industry was a main driver of growth in the first quarter. In the second quarter it did not contribute “particularly” to growth, Danmarks Statistik states. That shift accounts for much of the gap between the two quarters.
The statistics office also notes that pharmaceutical output rose early in 2026 while export prices fell. Higher volumes lift measured production and GDP. They do not automatically lift company earnings by the same amount.
Tore Stramer, chief economist at Dansk Erhverv, calls growth in the first half of the year reasonable overall, even though some of the momentum has gone. In a written commentary, he says a significant part of the explanation for the slide is that consumers have begun to hold back on spending. His comments were issued in connection with the same data release, as published on the Dansk Erhverv key figures page.
Stramer adds that the high growth at the beginning of the year should be treated with caution. It reflects more medicine being sold at lower prices, which raises production without a matching rise in earnings. He describes the growth seen especially in early 2026 as anaemic, arguing that companies’ ability to make money has not kept pace with GDP.
Ekstra Bladet reports the same figures, putting second-quarter growth preliminarily at 0.3 percent with the first-quarter figure left unrevised at 1.5 percent. The outlet frames the picture as pointing toward an uncertain winter for the Danish economy, citing the fading pharmaceutical contribution and continued global uncertainty.
Danmarks Statistik also maintains an overview of the Danish economy, which places the new quarterly reading alongside the 1.5 percent figure recorded for the first quarter of 2026. The agency publishes national accounts on a fixed quarterly schedule, and Thursday’s release is the trigger for the current round of coverage.
Danish shares in the pharmaceutical sector have been closely watched through the year, and for those investing in stocks in Denmark the divergence between output and earnings has been a recurring theme in Stramer’s commentary.
